Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

Abstract

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results:18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.

Keywords: 18F-PSMA-1007; PET/CT; PSMA-PET; biochemical recurrence; peptides; prostate cancer.

MeSH terms

  • Aged
  • Biological Transport
  • Fluorine Radioisotopes*
  • Humans
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives*
  • Niacinamide / metabolism
  • Oligopeptides* / metabolism
  • Positron Emission Tomography Computed Tomography*
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Recurrence

Substances

  • Fluorine Radioisotopes
  • Oligopeptides
  • PSMA-1007
  • Niacinamide
  • Fluorine-18